Market Overview

Recombinetics Closes $34 Million in Series A Funding


Minnesota-based Biotech Company is a Global Leader in Gene-Editing
Animals for Human Therapies, Regenerative Medicine and Animal Health and

Recombinetics, a pioneer in gene-editing solutions for human health and
animal agriculture, today announced the completion of a $34 million
Series A financing round.

"We're pleased to announce the successful completion of our Series A
Round," said Tammy Lee, President and CEO of Recombinetics. "This
financing will allow us to accelerate commercialization of this
transformative science to help find cures for human diseases, develop
new regenerative medicine products and breed animals that are healthier
and more productive."

The Company's Founder, Dr. Scott Fahrenkrug, added, "The success of this
capital raise reflects confidence in the vision of Recombinetics'
founders, and in the ability of the Board of Directors and management
team to execute against that vision. The proceeds will accelerate the
commercialization of genetic solutions for animal agriculture, swine
preclinical research, and so-called "oinkubators" for producing
therapeutic cells, tissues and organs."

Proceeds will be used to accelerate new research and development by
adding scientists and expertise focused on emerging science, including
regenerative medicine; to continue to add to our robust intellectual
property and patent portfolio; expand the laboratory, animal care and
advanced reproductive facilities; and build out the business
development, product marketing and management team to take advantage of
licensing and co-development opportunities. In conjunction with this
financing, Recombinetics has converted or repaid all of its outstanding

About Recombinetics
Founded in 2008, Recombinetics (RCI) has
a single gene-editing technology platform that supports three business
lines: Acceligen (precision breeding to enhance health, well-being and
productivity in food animals and aquaculture); Surrogen (gene-edited
swine models of human diseases for biomedical research and pre-clinical
trials by pharmaceutical and medical device companies); and Regenevida
(development of human regenerative products including cells, tissues and
organ products in swine models for exotransplantation to humans).

Recombinetics has a global intellectual property portfolio, with 22
patents issued and more than 300 patent filings on gene-editing methods,
traits, and novel reproduction methods in animals. Learn more at

View Comments and Join the Discussion!